Associated Papers
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India.
Batra U et al.
South Asian Journal of Cancer, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.
Kiełbowski K et al.
Frontiers in Pharmacology, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.
Nakagawa Y et al.
Thoracic Cancer, 2022
Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.
Pasau T et al.
Frontiers in Oncology, 2022
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS et al.
Lung Cancer (amsterdam, Netherlands), 2021
Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling.
Yang P et al.
Oncotargets and Therapy, 2021
Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing.
Zhang C et al.
Oncotargets and Therapy, 2020
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Friedlaender A et al.
Current Treatment Options in Oncology, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T et al.
Respiratory Investigation, 2019
Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.
Johnson TW et al.
Acs Medicinal Chemistry Letters, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI et al.
Archives of Pathology & Laboratory Medicine, 2018
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT et al.
The Lancet. Oncology, 2017
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
Katayama R
Pharmacology & Therapeutics, 2017
Drug resistance in ALK-positiveNon-small cell lungcancer patients.
Qian M et al.
Seminars in Cell & Developmental Biology, 2017
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
Santarpia M et al.
Drug Design, Development and Therapy, 2017
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Gainor JF et al.
Cancer Discovery, 2016